About GENSCRIPT BIO Company

Kingsri Biotechnology Co., Ltd. (the “Company” or “Kingsley”, together with its subsidiaries, collectively the “Group”) is a widely recognized biotechnology company. Based on our proprietary gene synthesis technology and other technology and expertise related to life science research and applications, we have successfully established four main platforms, including (i) a life science service and product platform to provide one-stop solutions for the global research community; (ii) a biologics contract development and production organization (“CDMO”) platform; (iii) an industrial synthesis product platform; and (iv) a comprehensive global cell therapy platform. For the six months ended June 30, 2023 (the “Reporting Period”), the above four internally built platforms achieved growth in R&D up to commercial delivery. Since its establishment 21 years ago, the Group has been adhering to the mission of “using biotechnology to make people and nature healthier”. The business needs of our customers are the Group's top priority and the fundamental foundation for our long-term development. We have been improving the competitiveness of our customers by providing quality, fast delivery and cost effective services and products. Internally, we focus on optimizing operating processes and procedures, aiming for the highest quality of end-to-end delivery. Externally, we actively enhance the value of strategic collaboration with business partners aimed at building a healthy biotechnology ecosystem. We hope to make greater contributions to accelerating the development of the entire biotech and biopharmaceutical industry to achieve a win-win situation among all partners involved in the industry. The Group's business operations cover more than 100 countries around the world, and its legal entities include mainland China (“China”), the United States, Hong Kong, Japan, Singapore, the Netherlands, Ireland, the United Kingdom, South Korea and Belgium. As of June 30, 2023, our professional team consists of around 6,414 members. The services and products provided by the Life Sciences Services and Products Division cover gene synthesis, oligonucleotide synthesis, peptide synthesis, protein production, antibody development, and life science equipment and consumables. By serving early research and discovery projects in pharmaceutical, biotechnology, and academic institutions, our business makes a significant contribution to the global life science research community. The CDMO platform provides one-stop cell and gene therapy (“CGT”) development and biologics discovery, development and subsequent production services for customers around the world. During the reporting period, the CDMO business focused on global production capacity and commercial network expansion. Legend Biotech Co., Ltd. (“Legend” or “Legend Bio”) is a biopharmaceutical subsidiary of the Group that specializes in the discovery and development of novel cell therapies for tumors and other indications. The legendary lead candidate, cilta-cel (cilta-cel), is a chimeric antigen receptor T-cell therapy developed in collaboration with JanssenBiotech, Inc. (“Janssen”) to treat multiple myeloma (“MM”). Baisjie Biotechnology Co., Ltd. (“Baisjie”) is a subsidiary of the Group and is engaged in the synthetic biology business. BESGER uses our advanced enzyme engineering technology to develop products for the feed, alcohol, food and home care industries. We believe synthetic biology provides us with new technological and commercial opportunities.